Phase 2 Head and Neck Cancer Trial, Recruiting NCT05069857 Sponsor: Shanghai Jiao Tong University School of Medicine Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 2 Head and Neck Cancer Trial, Recruiting

NCT05069857
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 75 years old, of any gender
  • People who are able to carry out daily activities with little to no limitation (as measured by a standard health scale called ECOG, with a score of 0 to 2)
  • People who have been confirmed by a tissue biopsy to have a specific type of mouth cancer called oral squamous cell carcinoma, affecting areas such as the tongue, gums, cheeks, floor of the mouth, hard palate, or the area behind the back teeth
  • People whose cancer is at a moderately advanced stage (Stage III or IVA based on international staging guidelines)
  • People whose cancer cells show a high level of a protein called PD-L1, with a combined positive score greater than 10 (this is measured by a lab test on the cancer tissue)
  • People who have read and signed a consent form agreeing to take part in the trial

Who may not be able to join:

  • People who are still experiencing significant side effects from a previous cancer treatment that have not fully resolved
  • People who have had serious heart problems, such as a heart attack or significant heart disease, within the 3 months before joining
  • People who currently have a serious active infection
  • People with high blood pressure that cannot be controlled with medication (above 150/90 mmHg), or who have had a stroke, heart attack, unstable chest pain, significant heart failure, or serious irregular heartbeat within 6 months before the screening visit
  • People whose blood test results show low levels of white blood cells, red blood cells (haemoglobin), or platelets
  • People whose liver function tests show results significantly above the normal range
  • People whose kidney function tests show creatinine levels significantly above the normal range
  • People who have previously had radiotherapy to the face, jaw, or neck area
  • People who are pregnant or currently breastfeeding
  • People who have participated in another clinical trial within the 30 days before joining
  • People whom the trial doctors consider unsuitable for participation for any other reason (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Lai-ping Zhong, MD, PhD, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

Phone: +862123271699

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shanghai Jiao Tong University School of Medicine
Registry
ClinicalTrials.gov
Start date
1 September 2021
Est. completion
30 August 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

2-year disease-free survival rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov